GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qualigen Therapeutics Inc (NAS:QLGN) » Definitions » Quick Ratio

Qualigen Therapeutics (Qualigen Therapeutics) Quick Ratio : 0.28 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Qualigen Therapeutics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Qualigen Therapeutics's quick ratio for the quarter that ended in Dec. 2023 was 0.28.

Qualigen Therapeutics has a quick ratio of 0.28. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Qualigen Therapeutics's Quick Ratio or its related term are showing as below:

QLGN' s Quick Ratio Range Over the Past 10 Years
Min: 0.18   Med: 0.68   Max: 4.26
Current: 0.28

During the past 4 years, Qualigen Therapeutics's highest Quick Ratio was 4.26. The lowest was 0.18. And the median was 0.68.

QLGN's Quick Ratio is ranked worse than
92.72% of 1553 companies
in the Biotechnology industry
Industry Median: 3.49 vs QLGN: 0.28

Qualigen Therapeutics Quick Ratio Historical Data

The historical data trend for Qualigen Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qualigen Therapeutics Quick Ratio Chart

Qualigen Therapeutics Annual Data
Trend Mar20 Dec21 Dec22 Dec23
Quick Ratio
0.18 4.26 1.07 0.28

Qualigen Therapeutics Quarterly Data
Jun19 Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.07 0.73 0.39 0.58 0.28

Competitive Comparison of Qualigen Therapeutics's Quick Ratio

For the Biotechnology subindustry, Qualigen Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qualigen Therapeutics's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Qualigen Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Qualigen Therapeutics's Quick Ratio falls into.



Qualigen Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Qualigen Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(1.167-0)/4.137
=0.28

Qualigen Therapeutics's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(1.167-0)/4.137
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qualigen Therapeutics  (NAS:QLGN) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Qualigen Therapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Qualigen Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Qualigen Therapeutics (Qualigen Therapeutics) Business Description

Traded in Other Exchanges
Address
2042 Corte del Nogal, Suite B, Carlsbad, CA, USA, 92011
Qualigen Therapeutics Inc is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases using nanoparticle coating technology. It is a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics. The Company has viewed its operations and managed its business in one segment operating mainly within the United States and Israel.
Executives
Michael S. Poirier director, officer: Chairman, President and CEO 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Amy S. Broidrick director 1440 VALLE GRANDE, ESCONDIDO CA 92025
Kurt H Kruger director 100 FOXBOROUGH BLVD, SUITE 240, FOXBOROUGH MA 02035
Tariq Arshad officer: SVP/Chief Medical Officer 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Christopher L. Lotz officer: Vice President of Finance, CFO 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 90211
Emery Sidney W Jr director C/O QUALIGEN THERAPEUTICS, INC., 2042 CORTE DEL NOGAL, CARLSBAD CA 92011
Richard A. David director 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Wajdi Abdul-ahad officer: VP, R&D, CSO 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Shishir K. Sinha officer: VP of Operations 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Sekisui Diagnostics, Llc 10 percent owner 1 WALL STREET, BURLINGTON MA 01803
Matthew E Korenberg director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Noah Doyle director C/O RITTER PHARMACEUTICALS INC., 1801 CENTURY PARK EAST, SUITE 1820, LOS ANGELES CA 90096
John W Beck officer: Chief Financial Officer C/O RITTER PHARMACEUTICALS, INC., 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES CA 90067
Jeffrey S Benjamin officer: VP of Finance 3885 CRESTWOOD PARKWAY, SUITE 550, DULUTH GA 30096
William M. Merino director C/O RITTER PHARMACEUTICALS INC., 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES CA 90067

Qualigen Therapeutics (Qualigen Therapeutics) Headlines

From GuruFocus